Literature DB >> 33341826

Risk of gestational hypertension in pregnancies complicated with ovarian hyperstimulation syndrome.

Aleksandar Dobrosavljevic1, Snezana Rakic2.   

Abstract

OBJECTIVE: Ovarian hyperstimulation syndrome (OHSS) is the most common iatrogenic complication due to ovulation stimulation during assisted reproductive technology. Pathophysiology of this syndrome is not completely clarified, and there is no some specific treatment. Human chorionic gonadotropin is considered as the most significant factor in etiopathogenesis of OHSS. The results of some clinical studies related to influence of OHSS on pregnancy are variable. The aim of this study was to investigate hypertensive disease of pregnancies in patients admitted to hospital due to severe forms of OHSS with reference to maternal characteristics.
METHODOLOGY: A case control study was conducted at the Obstetrics and Gynaecology Clinic "Narodni Front" and involved 50 patients admitted to hospital due to severe form of OHSS during a period from January 2008 to March 2015. A control group was created based on age and it involved 59 patients with pregnancy achieved with IVF/ICSI during the same period, but in which OHSS did not occur. For comparing mean values of continuous variables, Independent samples t test was applied.
RESULTS: Patients with pregnancy complicated by OHSS, had considerably higher rate of hypertension (14% vs. 3.2 %, p=0.046).
CONCLUSIONS: Pregnancies achieved by IVF/ICSI, being complicated with severe OHSS could be related to gestational hypertension.

Entities:  

Keywords:  IVF/ICSI, ovarian hyperstimulation syndrome, perinatal outcomes, hypertensive disease of pregnancy.zzm321990 zzm321990

Mesh:

Year:  2020        PMID: 33341826     DOI: 10.5455/JPMA.20387

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  1 in total

1.  Clinical Evaluation of Pinggan Yiqi Yangshen Recipe Combined with Labetalol Hydrochloride and Magnesium Sulfate in the Treatment of PIH.

Authors:  Ping Li; Jie Zhao; Peipei Gao; Hongcui Qu
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-28       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.